Phases & Checklist

Track your progress through the acceleration program.

Bronze Program

Overall Progress

65% Completed
Phase 1: Onboarding
Oct 15 - Dec 01, 2025
Completed
Program structure
Phases, sections and points of interest
In Progress
Note: Structure of the Bronze program as defined in Admin → Programs → Program Structure.
Point of interest Evidence Rating Status
Team
Management Team
Names, past positions and education of team Completed
Relevant startup, fundraising, exit experience — In Review
Team dynamics — To do
Completeness of other roles (eg. ops, BD, etc) 1 — In Review
Board
Names and background Completed
Expertise, meeting frequency, record keeping quality, network Completed
Scientific Advisory Board
Names, background and affiliations Completed
Relevant expertise Completed
Market
Problem statement
Clarity of problem to be addressed Completed
Social or economic impact of problem Completed
Key assumptions — In Review
Addressable market
TAM, SAM, SOM Completed
CAGR — In Review
Market trends
Diagnostic and prognostic trends of patient population Completed
Competition
Competitive landscape
Direct and indirect — To do
Funding status and development speed of competitors Completed
Identification of failed programmes, and why — In Review
Differentiation
Clarity of differentiation in terms of safety, efficacy, convenience, etc. Completed
Likelihood of differentiation being clinically meaningful rather than incremental — To do
IP
Patent strategy Completed
FTO performed? — To do
Pipeline
Lead programme
Definition of lead indication (eg. subtype, biomarker presence, resistant population, etc) — To do
Rationale for lead indication/target choice, was it selected after a proper evaluation Completed
SOC
SOC of lead programme Completed
Addressing issue with SOC — To do
Scientific rationale
Strength of biological rationale Completed
Genetic evidence — To do
Relevance/translatability of selected preclinical models — To do
Clinical Development Plan
Clinical evidence for modality or target Completed
Appropriate clinical readouts — To do
Strength of safety or efficacy readout (anomalies, cohort size, trial design) relative to SOC and key competitors — In Review
CMC partners, TPP, Development plan — To do
Regulatory
Roadmap with anticipated timeline, milestones, and will they still be competitive by then — To do
Accelerated regulatory path options — To do
Other programmes
Rationale for other programmes Completed
Synergistic or diversified risk — To do
Financials
Funding
Past funding raised and whether reasonable for progress seen — To do
Ticket size requested relative to inflection point desired — In Review
Use of proceeds Completed
KOL Calls
Experts
Strength of scientific fundamentals — To do
Clinical positioning — To do
Risks and red flags — To do
Investor meetings
Mar 16 - Apr 30, 2026
Upcoming